@article {ShethP07.034作者={凯文Sheth阿尔伯特Yoo和罗伯托·冈萨雷斯和威廉金伯利Zeshan乔杜里和约旦榆树和斯文雅各布森和斯蒂芬·戴维斯和杰弗里唐南和格里高利·阿尔巴尼船尾},title ={半球体积与恶性梗死后神经恶化和结果(P07.034)},体积={78}={1}补充数量,页面= {P07.034——P07.034} ={2012},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:我们假设MRI脑体积增加卒中后第一天与神经退化和功能结果恶性水肿患者。首页背景70 \ %的恶性梗死患者死于继发性脑水肿。治疗策略发展的基本挑战是缺乏验证成像脑水肿的标志。设计/方法:我们进行了一项回顾性分析绰号研究MRI {\ textquoteright}年代在中风发作,3 - 5天。我们选择患者急性弥散加权成像体积\ > 82 cc,这是很好的预测恶性水肿。涉及的半球是由两个独立的手动了读者,和卷测量使用分析软件。我们评估了两分的协议,扫描和协会之间的体积变化体积变化与早期神经功能恶化(结束:署恶化> = 4分),90天的改良Rankin规模(夫人)得分0 - 4和死亡率。结果:12符合研究标准的患者,平均基线和随访醉酒驾车病变大小是138立方厘米和234立方厘米,分别。平均随访MRI时间是62小时。和合读者\之间的相关系数> 0.90半球和心室容积评估。意思是半球体积百分比增加16.2 {\ textpm} 8.3 \ % (p \ <。)。半球百分比增长预测结束(曲线下的面积(AUC) = 0.92, p = 0.0005)和90天的夫人0 - 4 (AUC 0.80, p = 0.02)。Conclusions: In this exploratory analysis of severe ischemic stroke patients, statistically significant changes in hemisphere and ventricular volumes within the first week are consistent with expected changes of cerebral edema. MRI-based analysis of hemisphere growth appears to be a suitable biomarker for edema formation.Disclosure: Dr. Sheth has nothing to disclose. Dr. Yoo has nothing to disclose. Dr. Gonzalez has nothing to disclose. Dr. Kimberly has nothing to disclose. Dr. Chaudhry has nothing to disclose. Dr. Elm has nothing to disclose. Dr. Jacobson has received personal compensation for activities with Remedy Pharmaceuticals as the CEO.Dr. Jacobson has received compensation for serving as the CEO of Remedy Pharmaceuticals.Dr. Jacobson holds stock and/or stock options in Remedy Pharmaceuticals. Dr. Davis has received personal compensation for activities with Boehringer Ingelheim, Sanofi- Aventis, and Ever Pharma. Dr. Davis has received personal compensation in an editorial capacity for Associate Editor of Cerebrovascular Diseases. Dr. Donnan has nothing to disclose. Dr. Albers has received personal compensation for activities with Genentech and Lundbeck as a member of the Advisory Board. Dr. Albers has received research support from Genetech, Aventis, Sanofi, BI, Ono, and AstraZeneca. Dr. Stern has received personal compensation in an editorial capacity for the Neurologist. Dr. Stern has received research support from Remedy Pharmaceuticals, Inc.Thursday, April 26 2012, 14:00 pm-18:30 pm}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/78/1_Supplement/P07.034}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }